A layered approach to care is described with lifestyle interventions being a key feature of the updated recommendations. The recommendations now include therapies proven to improve cardiovascular and kidney outcomes in patients with diabetes and CKD.

This large cohort study evaluated the frequency of 70 long COVID outcomes in unvaccinated individuals with mild COVID infection matched to uninfected individuals and to vaccinated individuals. Anosmia and dysgeusia were the most frequently reported long COVID symptoms with the risk being dramatically increasing at 30 days to 6 months post infection and falling rapidly thereafter. Mild COVID generated an 85% increased risk of cognitive impairment an 80% increased risk of dyspnea and weakness and a nearly 50% increased risk for palpitations. The findings were consistent across all COVID variants and were more marked in adults than children. Vaccinated individuals with breakthrough infection had similar risk for all these outcomes with the exception of dyspnea, for which the risk was lower in vaccinated persons.

Per this Nature article highlighted on MashupMD, inadequate funding plus fears of rebound and side effects are hobbling the availability and use of this potentially lifesaving antiviral.

The original monovalent vaccines continue to protect against serious disease from the new variants. If SARS-CoV-2 variants evolve to resist the protection against severe disease offered by vaccination or previous infection, then variant-specific vaccines will be needed. Otherwise, this authority recommends we “stop trying to prevent all symptomatic infections in healthy, young people by boosting them with vaccines containing mRNA from strains that might disappear a few months later.”

Authors found that in 23.6% of a random sample of 2,809 admissions, there were at least one adverse event. 316 of the 978 adverse events were classified as having a significant or higher severity level, and 222 were deemed to be preventable. In 6.8% of all admissions, an adverse event that could have been avoided happened, and in 1% of those cases, the incident had a serious or higher severity rating. Seven people passed away, one of which was thought to be avoidable. The most frequent adverse events (representing 39.0% of all occurrences) were adverse medication events, which were followed by surgical or other procedural events (30.4%), patient-care events (15.0%), and infections related to medical care (11.9%).

Clinically significant anxiolytic and antidepressant benefits were seen in anxious depression patients after TMS in all samples, with average reductions in GAD-7 and PHQ-9 scores of 50% or more. The PHQ-9 scores for both the anxious and nonanxious depression groups improved equally. The worried group, however, scored higher both at the beginning of the study and after TMS, leading to significantly lower categorical rates of response and remission in depressive symptoms. The shift in anxiety and depressive symptoms substantially correlated among individuals who had anxious depression.